Darmstadt, November 25, 2022 – The flu season has begun and totally different virus variants are additionally circulating in Germany. With the flu checks from biotechnology firm R-Biopharm, sufferers shortly have certainty: Its RIDA®GENE Flu assays additionally reliably detect the 2 novel variants. The corporate made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the UK, and the H3N2 subtype, which was rampant in Denmark within the spring and is at the moment dominating influenza exercise in Germany.
“Mutations within the goal gene (MP gene) can have an effect on the diagnostic efficiency of influenza screening assays, producing false-negative check outcomes,” explains Dr. Andreas Simons, Head of Product Administration at R-Biopharm. “Alignments of the detection methods we used with the described sequences of the 2 novel virus variants confirmed no mismatches. Their dependable detection is just not affected by the described mutations.”
This implies laboratories can proceed to reliably verify or rule out influenza infections utilizing R-Biopharm’s RIDA®GENE (PG0505, PG0545, PG6825) assays. The checks are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
About R-Biopharm
R-Biopharm AG, positioned in Darmstadt, is considered one of Germany’s main biotechnology corporations. Based in 1988, the corporate is family-run within the second technology and considers itself as a pioneer for well being and high quality of life. Its aspiration: to offer the very best potential precision, security, readability and certainty in prevention, remedy and therapeutic. To this finish, R-Biopharm develops applied sciences, merchandise and options for Scientific Diagnostics, Diet Care and Meals and Feed Analytics – and does so in internationally acknowledged high-quality. R-Biopharm is the world market chief for check methods within the subject of allergen evaluation.
R-Biopharm unites analysis, improvement and gross sales beneath one roof as a way to reply to ever new challenges with agile processes and to accompany the steadily rising world inhabitants into a brand new well being period. The corporate is represented in additional than 120 international locations – by way of 29 subsidiaries and 120 distributors. It employs round 1,400 folks worldwide (690 at its headquarters in Darmstadt) and was repeatedly acknowledged with the “Sustainability Award” for sustainable and worthwhile progress.
Press contact:
Simone Feiler
Head of Company Model Communication
https://r-biopharm.com/de/
https://r-biopharm.com/de/kontakt/presse/
https://r-biopharm.com/de/news-presse/download-galerie/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Cellphone: 0 61 51 – 81 02-538
Cellular: 0 160 – 55 273 60
Fax: 0 61 51 – 81 02-40
E-mail: s.feiler@r-biopharm.de
